Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch LLP | PRODUCT CODE: 1188090

Cover Image

PUBLISHER: 360iResearch LLP | PRODUCT CODE: 1188090

Biosimilars Market Research Report by Indication (Autoimmune Diseases, Blood Disorders, and Chronic Diseases), Product, Manufacturing, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, High Inflation - Global Forecast 2023-2030

PUBLISHED:
PAGES: 234 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Online Access - 1 Year (Single User License)
USD 3949
PDF & Excel + Online Access - 1 Year (Single User License)
USD 4949
PDF & Excel + Online Access - 1 Year (Up to 5 User License)
USD 5949
PDF & Excel + Online Access - 1 Year (Site License)
USD 6949
PDF & Excel + Online Access - 1 Year (Enterprise User License)
USD 8949

Add to Cart

The Global Biosimilars Market size was estimated at USD 14.96 billion in 2022 and expected to reach USD 18.57 billion in 2023, projecting growth at a CAGR of 24.27% to reach USD 85.14 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Biosimilars Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people's lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Biosimilars Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Biosimilars Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Biosimilars Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Biosimilars Market in order to forecast the revenues and analyze the trends in each of the following sub-markets.

Based on Indication, the market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.

Based on Product, the market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.

Based on Manufacturing, the market is studied across Contract Manufacturing and In-House Manufacturing.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Biosimilars Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Biosimilars Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Biosimilars Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Biosimilars Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor's strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market, including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., Eli Lilly and Company, Innovent Biologics, Inc., LG Chem Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sandoz International GmbH, and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biosimilars Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?

4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?

5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?

6. What is the market share of the leading vendors in the Global Biosimilars Market?

7. What modes and strategic moves are considered suitable for entering the Global Biosimilars Market?

Product Code: MRR-4358917D6591

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing pressure to reduce healthcare expenditure
      • 5.1.1.2. Increasing need for pharmaceutical drugs
      • 5.1.1.3. Lower cost biosimilars drugs than original biologics
    • 5.1.2. Restraints
      • 5.1.2.1. Reluctance of physicians to prescribe biosimilars
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in biosimilar production processes
      • 5.1.3.2. Supportive government initiative to develop biosimilars
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and laws
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Cumulative Impact of Russia-Ukraine Conflict
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Threat of Substitutes
    • 5.5.4. Threat of Substitutes
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework
  • 5.8. Client Customization
    • 5.8.1. Technical Development & Trends
    • 5.8.2. Regulatory Submissions Timelines
    • 5.8.3. Clinical Bio Analytics and Technical Timelines and Related FTEs
    • 5.8.4. Drugs Loosing Patent: 2018-2022

6. Biosimilars Market, by Indication

  • 6.1. Introduction
  • 6.2. Autoimmune Diseases
  • 6.3. Blood Disorders
  • 6.4. Chronic Diseases
  • 6.5. Growth Hormone Deficiency
  • 6.6. Infectious Diseases
  • 6.7. Oncology

7. Biosimilars Market, by Product

  • 7.1. Introduction
  • 7.2. Recombinant Glycosylated Proteins
    • 7.3.1. Erythropoietin
    • 7.3.2. Follitropin
    • 7.3.3. Monoclonal Antibodies
      • 7.3.4.1. Adalimumab
      • 7.3.4.2. Infliximab
      • 7.3.4.3. Rituximab
  • 7.3. Recombinant Non-Glycosylated Proteins
    • 7.4.1. Granulocyte Colony-Stimulating Factor
    • 7.4.2. Insulin
    • 7.4.3. Interferons
      • 7.4.4.1. Interferon-Alpha
      • 7.4.4.2. Interferon-Beta
    • 7.4.4. Recombinant Human Growth Hormone
  • 7.4. Recombinant Peptides
    • 7.5.1. Calcitonin
    • 7.5.2. Glucagon

8. Biosimilars Market, by Manufacturing

  • 8.1. Introduction
  • 8.2. Contract Manufacturing
  • 8.3. In-House Manufacturing

9. Americas Biosimilars Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Biosimilars Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Biosimilars Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis, By Key Player
  • 12.3. Market Share Analysis, By Key Player
  • 12.4. Product Portfolio Analysis, By Key Player
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AMEGA Biotech S.A.
  • 13.2. Amgen Inc.
  • 13.3. Apotex Inc.
  • 13.4. Biosidus S.A.
  • 13.5. Dr. Reddy's Laboratories Limited
  • 13.6. Eden Biologics, Inc.
  • 13.7. Eli Lilly and Company
  • 13.8. Innovent Biologics, Inc.
  • 13.9. LG Chem Ltd.
  • 13.10. Merck & Co., Inc.
  • 13.11. Mylan N.V.
  • 13.12. Novartis AG
  • 13.13. Pfizer Inc.
  • 13.14. Sandoz International GmbH
  • 13.15. Teva Pharmaceutical Industries Ltd.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
Product Code: MRR-4358917D6591

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOSIMILARS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOSIMILARS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 6. GLOBAL BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
  • FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 9. GLOBAL BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 10. GLOBAL BIOSIMILARS MARKET DYNAMICS
  • FIGURE 11. GLOBAL BIOSIMILARS MARKET PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 14. GLOBAL BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
  • FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD BILLION)
  • FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2018-2030 (USD BILLION)
  • FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD BILLION)
  • FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD BILLION)
  • FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD BILLION)
  • FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD BILLION)
  • FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 23. GLOBAL BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
  • FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD BILLION)
  • FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD BILLION)
  • FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2018-2030 (USD BILLION)
  • FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
  • FIGURE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2018-2030 (USD BILLION)
  • FIGURE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2018-2030 (USD BILLION)
  • FIGURE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2018-2030 (USD BILLION)
  • FIGURE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD BILLION)
  • FIGURE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2018-2030 (USD BILLION)
  • FIGURE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2018-2030 (USD BILLION)
  • FIGURE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD BILLION)
  • FIGURE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2018-2030 (USD BILLION)
  • FIGURE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2018-2030 (USD BILLION)
  • FIGURE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2018-2030 (USD BILLION)
  • FIGURE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD BILLION)
  • FIGURE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2018-2030 (USD BILLION)
  • FIGURE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2018-2030 (USD BILLION)
  • FIGURE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2022 VS 2030 (%)
  • FIGURE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 43. GLOBAL BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY MANUFACTURING, 2030
  • FIGURE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD BILLION)
  • FIGURE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD BILLION)
  • FIGURE 46. AMERICAS BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 47. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 49. AMERICAS BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 50. ARGENTINA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 51. BRAZIL BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 52. CANADA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 53. MEXICO BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 54. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 55. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 56. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 57. UNITED STATES BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
  • FIGURE 58. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 59. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 60. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 61. ASIA-PACIFIC BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 62. AUSTRALIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 63. CHINA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 64. INDIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 65. INDONESIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 66. JAPAN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 67. MALAYSIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 68. PHILIPPINES BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 69. SINGAPORE BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 70. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 71. TAIWAN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 72. THAILAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 73. VIETNAM BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 74. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 75. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 76. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
  • FIGURE 77. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
  • FIGURE 78. DENMARK BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 79. EGYPT BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 80. FINLAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 81. FRANCE BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 82. GERMANY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 83. ISRAEL BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 84. ITALY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 85. NETHERLANDS BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 86. NIGERIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 87. NORWAY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 88. POLAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 89. QATAR BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 90. RUSSIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 91. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 92. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 93. SPAIN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 94. SWEDEN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 95. SWITZERLAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 96. TURKEY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 97. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 98. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • FIGURE 99. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX, 2022
  • FIGURE 100. GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022
  • FIGURE 101. GLOBAL BIOSIMILARS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

LIST OF TABLES

  • TABLE 1. GLOBAL BIOSIMILARS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
  • TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD BILLION)
  • TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2018-2030 (USD BILLION)
  • TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD BILLION)
  • TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD BILLION)
  • TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD BILLION)
  • TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD BILLION)
  • TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD BILLION)
  • TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD BILLION)
  • TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2018-2030 (USD BILLION)
  • TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
  • TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2018-2030 (USD BILLION)
  • TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2018-2030 (USD BILLION)
  • TABLE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2018-2030 (USD BILLION)
  • TABLE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD BILLION)
  • TABLE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2018-2030 (USD BILLION)
  • TABLE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2018-2030 (USD BILLION)
  • TABLE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 56. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD BILLION)
  • TABLE 57. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 58. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 59. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2018-2030 (USD BILLION)
  • TABLE 60. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 61. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 62. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2018-2030 (USD BILLION)
  • TABLE 63. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 64. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 65. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2018-2030 (USD BILLION)
  • TABLE 66. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 67. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 68. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD BILLION)
  • TABLE 69. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 70. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 71. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2018-2030 (USD BILLION)
  • TABLE 72. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 73. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 74. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2018-2030 (USD BILLION)
  • TABLE 75. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 76. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 77. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 78. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 79. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 80. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 81. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 82. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 83. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD BILLION)
  • TABLE 84. AMERICAS BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 85. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
  • TABLE 86. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 87. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 88. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 89. ARGENTINA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 90. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 91. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 92. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 93. BRAZIL BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 94. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 95. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 96. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 97. CANADA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 98. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 99. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 100. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 101. MEXICO BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 102. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 103. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 104. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 105. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 106. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
  • TABLE 107. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 108. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 109. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 110. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 111. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
  • TABLE 112. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 113. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 114. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 115. AUSTRALIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 116. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 117. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 118. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 119. CHINA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 120. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 121. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 122. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 123. INDIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 124. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 125. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 126. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 127. INDONESIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 128. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 129. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 130. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 131. JAPAN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 132. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 133. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 134. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 135. MALAYSIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 136. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 137. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 138. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 139. PHILIPPINES BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 140. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 141. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 142. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 143. SINGAPORE BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 144. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 145. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 146. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 147. SOUTH KOREA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 148. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 149. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 150. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 151. TAIWAN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 152. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 153. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 154. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 155. THAILAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 156. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 157. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 158. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 159. VIETNAM BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 160. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 161. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 162. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 168. DENMARK BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 169. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 170. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 171. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 172. EGYPT BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 173. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 174. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 175. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 176. FINLAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 177. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 178. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 179. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 180. FRANCE BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 181. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 182. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 183. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 184. GERMANY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 185. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 186. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 187. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 188. ISRAEL BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 189. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 190. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 191. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 192. ITALY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 193. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 194. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 195. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 196. NETHERLANDS BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 197. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 198. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 199. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 200. NIGERIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 201. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 202. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 203. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 204. NORWAY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 205. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 206. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 207. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 208. POLAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 209. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 210. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 211. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 212. QATAR BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 213. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 214. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 215. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 216. RUSSIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 217. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 218. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 219. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 220. SAUDI ARABIA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 221. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 222. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 223. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 224. SOUTH AFRICA BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 225. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 226. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 227. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 228. SPAIN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 229. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 230. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 231. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 232. SWEDEN BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 233. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 234. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 235. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 236. SWITZERLAND BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 237. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 238. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 239. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 240. TURKEY BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 241. TURKEY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 242. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 243. TURKEY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 244. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 245. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 246. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 247. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 248. UNITED KINGDOM BIOSIMILARS MARKET SIZE, 2018-2030 (USD BILLION)
  • TABLE 249. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
  • TABLE 250. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
  • TABLE 251. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD BILLION)
  • TABLE 252. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
  • TABLE 253. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
  • TABLE 254. GLOBAL BIOSIMILARS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
  • TABLE 255. GLOBAL BIOSIMILARS MARKET RANKING, BY KEY PLAYER, 2022
  • TABLE 256. GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 257. GLOBAL BIOSIMILARS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
  • TABLE 258. GLOBAL BIOSIMILARS MARKET MERGER & ACQUISITION
  • TABLE 259. GLOBAL BIOSIMILARS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 260. GLOBAL BIOSIMILARS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 261. GLOBAL BIOSIMILARS MARKET INVESTMENT & FUNDING
  • TABLE 262. GLOBAL BIOSIMILARS MARKET AWARD, RECOGNITION, & EXPANSION
  • TABLE 263. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!